Certified by Founder
Lodge
ARTBIO
start up
United States
- Cambridge, Massachusetts
- 08/12/2023
- Series A
- $90,000,000
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
- Industry Biotechnology Research
- Website https://artbio.com/
- LinkedIn https://www.linkedin.com/company/artbio-inc/
Related People
Emanuele OstuniFounder
Switzerland -
Reinach, Basel-Country
Specialties: Commercial execution, Strategy, M&A, Business Development, Entrepreneurship,
RenoFi | $22,000,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)
MightyFly | $10,000,000 | (Mar 4, 2026)
Qura | $1,739,595 | (Mar 4, 2026)
KeyCare | $27,400,000 | (Mar 4, 2026)
Devotion(US) | $4,000,000 | (Mar 4, 2026)
Burst | $2,100,000 | (Mar 4, 2026)
JetStream Security Inc. | $34,000,000 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
EGI Battery | $10,000,000 | (Mar 4, 2026)
Bindbridge | $3,800,000 | (Mar 4, 2026)
Inhouse | $5,000,000 | (Mar 3, 2026)